These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 32562016)
1. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Hinchcliff M; O'Reilly S Curr Rheumatol Rep; 2020 Jun; 22(8):42. PubMed ID: 32562016 [TBL] [Abstract][Full Text] [Related]
8. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB; Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834 [TBL] [Abstract][Full Text] [Related]
9. Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Atanelishvili I; Akter T; Noguchi A; Vuyiv O; Wollin L; Silver RM; Bogatkevich GS Clin Exp Rheumatol; 2019; 37 Suppl 119(4):115-124. PubMed ID: 31573469 [TBL] [Abstract][Full Text] [Related]
10. Advances in biological and targeted therapies for systemic sclerosis. Mulcaire-Jones E; Low AHL; Domsic R; Whitfield ML; Khanna D Expert Opin Biol Ther; 2023 Apr; 23(4):325-339. PubMed ID: 36964674 [TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M Front Immunol; 2020; 11():1990. PubMed ID: 33013852 [TBL] [Abstract][Full Text] [Related]
12. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043 [TBL] [Abstract][Full Text] [Related]
13. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM; N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379 [TBL] [Abstract][Full Text] [Related]
14. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. Cutolo M; Gotelli E; Montagna P; Tardito S; Paolino S; Pizzorni C; Sulli A; Smith V; Soldano S Arthritis Res Ther; 2021 Aug; 23(1):205. PubMed ID: 34344444 [TBL] [Abstract][Full Text] [Related]
15. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Yamasaki Y; Kuwana M Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975 [TBL] [Abstract][Full Text] [Related]
16. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Kuwana M; Azuma A Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840 [TBL] [Abstract][Full Text] [Related]
17. Emerging targeted therapies in scleroderma lung and skin fibrosis. Maurer B; Distler O Best Pract Res Clin Rheumatol; 2011 Dec; 25(6):843-58. PubMed ID: 22265265 [TBL] [Abstract][Full Text] [Related]
18. An update on recent randomized clinical trials in systemic sclerosis. Boleto G; Avouac J; Allanore Y Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472 [TBL] [Abstract][Full Text] [Related]
19. Antifibrotics in systemic sclerosis. Martin-Lopez M; Carreira PE Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046 [TBL] [Abstract][Full Text] [Related]